Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01086475 · ClinicalTrials.gov registry record · Phase 3

D-Cycloserine and Social Skills Training in Autism Spectrum Disorders

A Phase 3 study of Autistic Disorder and Asperger's Disorder, sponsored by Indiana University.

Completed
Registry status
Phase 3
Development phase
68
Enrollment target
2
Study locations

NCT01086475 is a Phase 3 study of Autistic Disorder and Asperger's Disorder that has completed, run by Indiana University. The registered enrollment target is 68 participants, below the 111-participant average among 27 other Autistic Disorder trials with a reported enrollment target (39% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01086475, a Phase 3 study of Autistic Disorder and Asperger's Disorder, has completed, sponsored by Indiana University.

COMPLETED
Registry status
Phase 3
Development phase
68 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the effectiveness of D-cycloserine for improving social impairment in child with pervasive developmental disorders (PDD).

Interventions

  • DRUG Placebo
  • DRUG D-cycloserine

Study Locations (2)

Indiana

  • Riley Hospital for Children - Indianapolis

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2010-03
Est. Completion 2014-01
Phase Phase 3

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT01086475

The ClinicalTrials.gov registry entry for NCT01086475 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 111-participant average among 27 other Autistic Disorder trials with a reported enrollment target (39% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Autistic Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01086475 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Indiana, Ohio.

Frequently Asked Questions

What is clinical trial NCT01086475 about?

NCT01086475 is a clinical study titled "D-Cycloserine and Social Skills Training in Autism Spectrum Disorders". The purpose of this study is to determine the effectiveness of D-cycloserine for improving social impairment in child with pervasive developmental disorders (PDD).

What is the current status of trial NCT01086475?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2010-03. Estimated completion is 2014-01.

What conditions does trial NCT01086475 study?

This clinical trial studies the following conditions: Autistic Disorder, Asperger's Disorder, Pervasive Developmental Disorder NOS.

What interventions are being tested in trial NCT01086475?

The interventions under investigation include: Placebo (DRUG), D-cycloserine (DRUG).

Who is sponsoring clinical trial NCT01086475?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01086475 being conducted?

This trial has 2 study locations across Indiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autistic Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.